This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
XRAY or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands
by Zacks Equity Research
MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.
Merit Medical (MMSI) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Will Merit Medical (MMSI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
XRAY vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. MMSI: Which Stock Is the Better Value Option?
XRAY or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. MMSI: Which Stock Is the Better Value Option?
HTO or CWST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HTO vs. CWST: Which Stock Is the Better Value Option?
PFE or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
VNT vs. DUOL: Which Stock Is the Better Value Option?
by Zacks Equity Research
VNT vs. DUOL: Which Stock Is the Better Value Option?
XRAY vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. MMSI: Which Stock Is the Better Value Option?
FIVN vs. INFA: Which Stock Is the Better Value Option?
by Zacks Equity Research
FIVN vs. INFA: Which Stock Is the Better Value Option?
ALGN vs. MMSI: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALGN vs. MMSI: Which Stock Is the Better Value Option?
MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio
by Zacks Equity Research
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.
LH vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. MMSI: Which Stock Is the Better Value Option?
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
by Zacks Equity Research
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
Compared to Estimates, Merit Medical (MMSI) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 14.67% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Labcorp (LH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Segmental Performance Drive West Pharmaceutical's Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical Services' first-quarter results are likely to reflect growth amid pharma stabilization, biologics rebound & contract manufacturing gains.
What Analyst Projections for Key Metrics Reveal About Merit Medical (MMSI) Q1 Earnings
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Merit Medical (MMSI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Will Merit Medical (MMSI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical Stock Slips Despite the Launch of New Ventrax System
by Zacks Equity Research
MMSI launches the Ventrax Delivery System, enhancing pulmonary access procedures with improved control, precision, and efficiency for interventionalists.